Novavax: positive results for Covid/flu vaccine

Published: 2025-06-12 08:34:55 ET NVAX

Published on 06/12/2025 at 08:34

Novavax announces that the first results from its Phase 3 trial of the COVID-19 and seasonal influenza (CIC) combination vaccine, as well as its standalone trivalent influenza vaccine (tNIV), show immune responses comparable to those of the reference vaccines Nuvaxovid and Fluzone HD.The study, conducted in approximately 2,000 adults aged 65 and older, was designed to collect descriptive data on three influenza strains (H1N1, H3N2, B) and SARS-CoV-2.Both vaccine candidates induced robust immune responses (2.4- to 5.7-fold increase from baseline) and were well tolerated, with more than 98% of adverse events reported as mild or moderate.mild or moderate. These results, which complement Phase 2 data, will be used to prepare a future Phase 3 program with a view to registration. Copyright (c) 2025 CercleFinance.com. All rights reserved.